To a large extent, the Coronavirus pandemic was an enabler of prescription volume growth for FIDSON. The firm recently published its financial result, reporting a 16.17% YoY increase in its second-quarter revenue to NGN4.45bn- the highest Q2 top-line performance in its history. On a cumulative note, revenue expanded by 11.31% to NGN8.21bn in the first half. The increase in sales of prescription medicines (Ethical Business unit), up by 24.23% solely fueled the aggregate top-line performance. On the contrary, Over-the-Counter (OTC) drug sales ebbed slightly by 2.25% to NGN3.51bn in H1:2020.
Click on the link below to access the full report:
